Abstract
HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as p95HER2. These fragments are emerging as a valuable biomarker for this subset of patients, who have a particularly poor prognosis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Biomarkers, Tumor / analysis*
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / metabolism*
-
Female
-
Humans
-
Peptide Fragments / analysis*
-
Receptor, ErbB-2 / genetics
-
Receptor, ErbB-2 / metabolism*
Substances
-
Biomarkers, Tumor
-
Peptide Fragments
-
Receptor, ErbB-2